Sodium butyrate in Irritable Bowel Syndrome
Open Access
- 16 June 2025
- journal article
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 82, 60166
Abstract
Irritable bowel syndrome (IBS) is a common functional gastrointestinal disorder characterized by abdominal pain, bloating, and altered bowel habits. Although its pathophysiology is not fully understood, factors such as gut microbiota imbalance, increased intestinal permeability, and low-grade inflammation are considered key contributors. Sodium butyrate, a short-chain fatty acid produced by bacterial fermentation of dietary fiber, plays an important role in gut health. It supports intestinal barrier function, reduces inflammation, and influences microbiota composition. This review summarizes current knowledge on the role of sodium butyrate in IBS, focusing on its mechanisms of action and clinical relevance. A literature review was conducted using databases such as PubMed and Google Scholar with relevant MeSH keywords. Preclinical and clinical studies indicate that sodium butyrate may help alleviate IBS symptoms by enhancing epithelial integrity and modulating inflammation. However, variations in study design and dosing limit clear conclusions. Further randomized trials are needed to confirm its efficacy and define optimal treatment strategies.Keywords
This publication has 20 references indexed in Scilit:
- Oral butyrate modulates the gut microbiota in patients with inflammatory bowel disease, most likely by reversing proinflammatory metabolic reprogramming of colonocytesNeurogastroenterology & Motility, 2020
- Tight Junction Structure and Function RevisitedTrends in Cell Biology, 2020
- Microbiota changes induced by microencapsulated sodium butyrate in patients with inflammatory bowel diseaseNeurogastroenterology & Motility, 2020
- Butyrate inhibits visceral allodynia and colonic hyperpermeability in rat models of irritable bowel syndromeScientific Reports, 2019
- Clinical response to fecal microbiota transplantation in patients with diarrhea-predominant irritable bowel syndrome is associated with normalization of fecal microbiota composition and short-chain fatty acid levelsScandinavian Journal of Gastroenterology, 2019
- Butyrate Does Not Protect Against Inflammation-induced Loss of Epithelial Barrier Function and Cytokine Production in Primary Cell Monolayers From Patients With Ulcerative ColitisJournal of Crohn's and Colitis, 2019
- Nonpharmacologic options for treating irritable bowel syndromeJAAPA, 2019
- Reduced efficacy of low FODMAPs diet in patients with IBS-D carrying sucrase-isomaltase ( SI ) hypomorphic variantsGut, 2019
- Fecal Clostridiales distribution and short‐chain fatty acids reflect bowel habits in irritable bowel syndromeEnvironmental Microbiology, 2018
- Sodium Butyrate Inhibits Inflammation and Maintains Epithelium Barrier Integrity in a TNBS-induced Inflammatory Bowel Disease Mice ModelEBioMedicine, 2018